EUVIMEDEUVIMED entdecken
Crossref

Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome

Martin Coly, David Adams, Shahram Attarian, Françoise Bouhour, Jean-Philippe Camdessanché, Guillaume Carey, Cécile Cauquil, Jean-Baptiste Chanson, Pascale Chrétien, Alain Créange, Emilien Delmont, Guillaume Fargeot und 18 weitere

Journal of Neurology · 2024-08 · 271 (8) · 4982-4990

DOI: 10.1007/s00415-024-12410-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurology, online erschienen am 20.05.2024. Verfasst von Martin Coly und 29 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Bicêtre University Hospital, 94276, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Gangliosides, Autoantibodies, Miller Fisher Syndrome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & PURPOSE: In this retrospective study, we aimed at defining the clinical, paraclinical and outcome features of acute neurological syndromes associated with anti-GQ1b antibodies. RESULTS: We identified 166 patients with neurological symptoms appearing in less than 1 month and anti-GQ1b antibodies in serum between 2012 and 2022. Half were female (51%), mean age was 50 years (4-90), and the most frequent clinical features were areflexia (80% of patients), distal upper and lower limbs sensory symptoms (78%), ophthalmoplegia (68%), sensory ataxia (67%), limb muscle weakness (45%) and bulbar weakness (45%). Fifty-three patients (32%) presented with complete (21%) and incomplete (11%) Miller Fisher syndrome (MFS), thirty-six (22%) with Guillain-Barre syndrome (GBS), one (0.6%) with Bickerstaff encephalitis (BE), and seventy-three (44%) with mixed MFS, GBS & BE clinical features. Nerve conduction studies were normal in 46% of cases, showed demyelination in 28%, and axonal loss in 23%. Anti-GT1a antibodies were found in 56% of cases, increased cerebrospinal fluid protein content in 24%, and Campylobacter jejuni infection in 7%. Most patients (83%) were treated with intravenous immunoglobulins, and neurological recovery was complete in 69% of cases at 1 year follow-up. One patient died, and 15% of patients relapsed. Age > 70 years, initial Intensive Care Unit (ICU) admission, and absent anti-GQ1b IgG antibodies were predictors of incomplete recovery at 12 months. No predictors of relapse were identified. CONCLUSION: This study from Western Europe shows acute anti-GQ1b antibody syndrome presents with a large clinical phenotype, a good outcome in 2/3 of cases, and frequent relapses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GangliosidesAutoantibodiesMiller Fisher SyndromeHumansFemaleMaleMiddle AgedAdultAgedRetrospective StudiesYoung AdultAdolescentAged, 80 and overChildChild, PreschoolGuillain-Barre Syndrome

Stichwörter der Autor:innen

Anti-GQ1b antibodiesBickerstaff’s brainstem encephalitisGuillain–Barre syndromeMiller-Fisher syndrome

Substanzen

GangliosidesGQ1b gangliosideAutoantibodies

Autor:innen und Institutionen

  • Neurology Department, Bicêtre University Hospital, 94276, Le Kremlin-Bicêtre, France.
  • French National Reference Center for Rare Neuropathies (CERAMIC), 94276, Le Kremlin-Bicêtre, France.
  • Sorbonne University, 75013, Paris, France.
  • INSERM U1195, Paris-Saclay University, 94276, Le Kremlin-Bicêtre, France.
  • Reference Centre for Neuromuscular Diseases PACA RARE, Filnemus, EURO-NMD, CHU Timone, 13005, Marseille, France.
  • Reference Centre for Neuromuscular Diseases PACA RARE, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Bron Cedex, France.

Zitieren

APA

Coly, M., Adams, D., Attarian, S., Bouhour, F., Camdessanché, J. P., Carey, G., Cauquil, C., Chanson, J. B., Chrétien, P., Créange, A., Delmont, E., Fargeot, G., Frachet, S., Gendre, T., Kuntzer, T., Labeyrie, C., Maisonobe, T., Michaud, M., Moulin, M., …, & Echaniz-Laguna, A. (2024). Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome. Journal of Neurology, 271(8), 4982-4990. https://doi.org/10.1007/s00415-024-12410-4

Vancouver

Coly M, Adams D, Attarian S, Bouhour F, Camdessanché JP, Carey G, et al. Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome. Journal of Neurology. 2024;271(8):4982-4990. doi:10.1007/s00415-024-12410-4

BibTeX
@article{Coly2024,
  author = {Coly, Martin and Adams, David and Attarian, Shahram and Bouhour, Françoise and Camdessanché, Jean-Philippe and Carey, Guillaume and Cauquil, Cécile and Chanson, Jean-Baptiste and Chrétien, Pascale and Créange, Alain and Delmont, Emilien and Fargeot, Guillaume and Frachet, Simon and Gendre, Thierry and Kuntzer, Thierry and Labeyrie, Céline and Maisonobe, Thierry and Michaud, Maud and Moulin, Maximilien and Nicolas, Guillaume and Noury, Jean-Baptiste and Péréon, Yann and Puma, Angela and Sole, Guilhem and Taithe, Frédéric and Tard, Céline and Théaudin, Marie and Timsit, Serge and Venditti, Laura and Echaniz-Laguna, Andoni},
  title = {Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome},
  journal = {Journal of Neurology},
  year = {2024},
  volume = {271},
  number = {8},
  pages = {4982--4990},
  doi = {10.1007/s00415-024-12410-4}
}
Kostenlos starten →